The document discusses COPD and its comorbidities. It defines COPD as a disease characterized by persistent airflow limitation associated with an inflammatory response in the lungs to noxious particles. COPD has several risk factors and a variable natural history. The key pathological changes occur in the central and peripheral airways, lung parenchyma, and pulmonary vasculature. This leads to several physiological abnormalities including airflow limitation, gas exchange impairment, pulmonary hypertension, and systemic effects. Diagnosis requires symptoms, risk factor exposure, and confirmation of persistent airflow limitation on spirometry. Assessment aims to determine disease severity and impact on health status and risk of future events. Comorbidities commonly occur and should be actively managed.
New technology called Electromagnetic Navigation Bronchoscopy® (ENB) that uses virtual bronchoscopy and real time 3-dimensional CT images that enable me to localize these peripheral lung nodules for diagnosis and treatment. This outpatient procedure is minimally invasive and therefore has a small risk of pneumothorax (2-3%) and its published diagnostic yield rates range from 67% - 86%
Asthma vs COPD - A quick summary of the differences between themLGM Pharma
Asthma is a lung disease that affects almost 20 million Americans. COPD, or chronic obstructive pulmonary disease is a chronic lung disease that afflicts 24 million patients in the U.S. COPD is mainly caused by smoking or secondhand smoke, while asthma can by caused by exposure to allergens, dust and air pollutants. Innovative treatments are needed to combat both asthma and COPD, and LGM Pharma provides quality API's for the R&D needs of clients seeking treatments for these lung diseases.
How to manage a case of acute exacerbation of COPD according to GOLD guidelines. Sincere thanks to Dr. Amardeep Toppo who has prepared most of this presentation.
New technology called Electromagnetic Navigation Bronchoscopy® (ENB) that uses virtual bronchoscopy and real time 3-dimensional CT images that enable me to localize these peripheral lung nodules for diagnosis and treatment. This outpatient procedure is minimally invasive and therefore has a small risk of pneumothorax (2-3%) and its published diagnostic yield rates range from 67% - 86%
Asthma vs COPD - A quick summary of the differences between themLGM Pharma
Asthma is a lung disease that affects almost 20 million Americans. COPD, or chronic obstructive pulmonary disease is a chronic lung disease that afflicts 24 million patients in the U.S. COPD is mainly caused by smoking or secondhand smoke, while asthma can by caused by exposure to allergens, dust and air pollutants. Innovative treatments are needed to combat both asthma and COPD, and LGM Pharma provides quality API's for the R&D needs of clients seeking treatments for these lung diseases.
How to manage a case of acute exacerbation of COPD according to GOLD guidelines. Sincere thanks to Dr. Amardeep Toppo who has prepared most of this presentation.
COPD is a lung disease that makes it hard to breathe. It is caused by damage to the lungs over many years, usually from smoking.
The main symptoms are:
• A long-lasting (chronic) cough.
• Mucus that comes up when you cough.
• Shortness of breath that gets worse when you exercise.
We would like to intoduce you with BREATHE FREE!
Read more on it, See: http://www.nirogam.com/product_detail/333/Breathe-Free-60-Capsules-(Organic)
We are committed to your wellness and promise to help you with any health concern you may have. Please feel free to contact us via email or phone.
Nirogam India Pvt. Ltd.
F-32 & 33, 1st Floor
DLF Centre Point, Sector – 11,
Bata Mor, Main Mathura Road,
Faridabad, Haryana (India) - 121006
Mob: +91-9958171405 # 9015525552
Ph: 0129-4076777, 4006805
Email: support@nirogam.com
Facebook: www.facebook.com/nirogam
Web: www.nirogam.com
Etiopathogenesis and pharmacotherapy of COPD
a. the pathophysiology of selected disease states and the rationale for drug therapy;
b. the therapeutic approach to management of these diseases;
c. the controversies in drug therapy;
d. the importance of preparation of individualised therapeutic plans based on diagnosis;
e. needs to identify the patient-specific parameters relevant in initiating drug therapy,
and monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects);
f. describe the pathophysiology of selected disease states and explain the rationale for
drug therapy;
g. summarise the therapeutic approach to management of these diseases including
reference to the latest available evidence;
h. discuss the controversies in drug therapy;
i. discuss the preparation of individualised therapeutic plans based on diagnosis; and
j. identify the patient-specific parameters relevant in initiating drug therapy, and
monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects).
A common, preventable and treatable disease, characterized by persistent respiratory symptoms and airflow limitation that are usually progressive and associated with an enhanced chronic inflammatory response in the airways and/or alveoli due to significant exposure to noxious particles or gases. (Vogelmeier et al., 2017).
Chronic obstructive pulmonary disease (COPD) is a common lung disease causing restricted airflow and breathing problems. It is sometimes called emphysema or chronic bronchitis. In people with COPD, the lungs can get damaged or clogged with phlegm. ppt aims in introduction of copd. just discussed asthma and chronic bronchitis.
only for educational purpose.
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation. The main symptoms include dyspnea, cough, and sputum production. COPD is caused by exposure to inhaled irritants, most often cigarette smoke, leading to chronic inflammation and structural changes in the lungs.
The predominant form of COPD is chronic bronchitis, which involves chronic cough and sputum production for at least 3 months per year for 2 consecutive years. This is associated with inflammation and eventual thickening of the bronchial tubes. Emphysema is another form of COPD characterized by permanent enlargement of airspaces and destruction of lung parenchyma.
The airflow limitation in COPD is due to a combination of parenchymal destruction (emphysema) and small airways disease (chronic bronchitis). The obstruction is generally progressive and irreversible. Diagnosis is based on symptoms, exposure history, and spirometry showing irreversible airflow limitation.
COPD treatment aims to reduce symptoms, improve exercise tolerance, prevent exacerbations, and slow disease progression. Smoking cessation is essential. Medications used include bronchodilators and inhaled steroids. Supplemental oxygen may be required in advanced disease. Exacerbations are treated with antibiotics, oral steroids, and other supportive therapies. Patients often have decreased quality of life and COPD is a leading cause of mortality worldwide.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
2. Reference :
1. Fishman’s Pulmonary Diseases and
Disorders Edition- 4
2. Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guideline: 2014
Update
3. American Thoracic Society and European
Respiratory Society guideline: 2004
Update
2
3. • Definition and Overview
• Pathology, Pathogenesis and
Pathophysiology
• Diagnosis and Assessment
• Therapeutic Options
• Manage Stable COPD
• Manage Exacerbations
• Comorbidities and Management
3
6. Natural history
• COPD has a variable natural history and not all
individuals follow the same course.
• It is increasingly apparent that COPD often has its
roots decades before the onset of symptoms
• Impaired growth of lung function during childhood
and adolescence, caused by recurrent infections or
tobacco smoking, may lead to lower maximally
attained lung function in early adulthood.
• This abnormal growth will, often combined with a
shortened plateau phase in teenage smokers,
increase the risk of COPD.
6
7. Natural history
The normal course of forced expiratory volume in one second (FEV1) over time (–––)
is compared with the result of impaired growth of lung function (–––), an accelerated
decline
(–––) and a shortened plateau phase (–––). All three abnormalities can be combined.7
8. Natural history
• An accelerated decline in lung function is nevertheless
still the single most important feature of COPD.
• COPD is generally a progressive disease, especially if
the patient’s exposure to noxious substances, most
often tobacco smoking, continues.
• If exposure is stopped, the disease may still progress,
mainly due to the decline in lung function that normally
occurs with ageing.
• Nevertheless, stopping exposure to noxious agents,
even after significant airflow limitation is present, can
result in some improvement in function and will slow
or even hold the progression of the disease.
8
12. Pathology, pathogenesis and
pathophysiology
COPD comprises pathological changes in
four different compartments of the lungs:
Central airways
Peripheral airways
Lung parenchyma and
Pulmonary vasculature
which are variably present in individuals with
the disease.
12
13. Pathology
Central airways (cartilaginous airways
>2mm of internal diameter)
• Bronchial glands hypertrophy and goblet cell
metaplasia occurs.
• Results in excessive mucous production or
chronic bronchitis.
• Cell infiltrates also occur in bronchial glands.
• Airway wall changes include squamous
metaplasia of the airway epithelium, loss of
cilia and ciliary dysfunction, and increased
smooth muscle and connective tissue. 13
14. • Different inflammatory cells predominate in
different compartments of the central
airways.
• In the airways wall these are lymphocytes,
predominantly of the CD8+ type, but as
the disease progresses neutrophils also
become prominent.
• In the airspaces, in addition to
lymphocytes, neutrophils and
macrophages can also be identified.
14
15. Peripheral airways (noncartilaginous
airways <2mm internal diameter)
• Bronchiolitis is present in the peripheral
airways at an early stage of the disease.
• There is pathological extension of goblet cells
and squamous metaplasia in the peripheral
airways.
• The inflammatory cells in the airway wall and
airspaces are similar to those in the larger
airways.
• As the disease progresses, there is fibrosis
and increased deposition of collagen in the
airway walls.
15
16. Lung parenchyma (respiratory
bronchioles, alveoli and capillaries)
• Emphysema, defined as an abnormal
enlargement of air spaces distal to the
terminal bronchioles, occurs in the lung
parenchyma in COPD.
• As a result of emphysema there is a
significant loss of alveolar attachments, which
contributes to peripheral airway collapse.
16
17. • There are two major types of
emphysema:
1) Centrolobular ( involves dilatation
and destruction of the respiratory
bronchioles); and
2) Panlobular emphysema ( involves
destruction of the whole of the acinus).
17
18. • The former is the most common type of
emphysema in COPD and is more prominent
in the upper zones, while the latter
predominates in patients with α1-antitrypsin
deficiency and is more prominent in the lower
zones.
• In the early stages of the disease, these are
microscopic lesions.
18
19. • During the course of the disease, they may
progress to macroscopic lesions or bullae
(defined as an emphysematous space >1 cm
in diameter).
• Bullous disease can also occur in the
absence of COPD.
• The inflammatory cell profile in the alveolar
walls and the airspaces is similar to that
described in the airways and persists
throughout the course of the disease.
• There is some evidence suggesting the
persistence of inflammation in the proximal
and distal airspaces after smoking cessation.19
20. Pulmonary vasculature
• Pulmonary vascular changes begin early
during the course of the disease.
• Initially, these changes are characterised by
thickening of the vessel wall and endothelial
dysfunction.
• These are followed by increased vascular
smooth muscle and infiltration of the vessel
wall by inflammatory cells, including
macrophages and CD8+ T lymphocytes.
20
21. • In advanced stages of the disease,
there is collagen deposition and
emphysematous destruction of the
capillary bed.
• Eventually, these structural changes
lead to pulmonary hypertension and
right ventricular dysfunction (cor
pulmonale).
21
22. Pathogenesis
• Tobacco smoking is the main risk factor for COPD,
although other inhaled noxious particles and gases
may also contribute.
• This causes an inflammatory response in the lungs
of all smokers.
• Some smokers display an exaggeration of this
normal, protective inflammatory response to these
inhalation exposures, which eventually causes
tissue destruction, impairs the defence mechanisms
that limit such destruction and disrupts the repair
mechanisms, leading to the characteristic
pathological lesions of COPD. 22
23. • In addition to inflammation, two other
processes that are also important in the
pathogenesis of COPD are an imbalance
of proteinases and antiproteinases in the
lungs, and oxidative stress.
Inflammation
• COPD is characterised by an increase in
neutrophils, macrophages and T-
lymphocytes (specifically CD8+) in various
parts of the lungs, which relate to the
degree of airflow limitation. 23
24. • There may be an increase in eosinophils in
some patients, particularly during
exacerbations.
• These inflammatory cells are capable of
releasing a variety of cytokines and
inflammatory mediators, most notably
leukotriene-4, interleukin-8 and tumour
necrosis factor-α.
• This inflammatory pattern is markedly different
from that seen in patients with bronchial
asthma.
• Inflammatory changes may persist after
quitting smoking. 24
25. Proteinase and antiprotease imbalance
• This may occur in COPD due to increased
production (or activity) of proteinases or
inactivation (or reduced production) of
antiproteinases.
• Cigarette smoke (and possibly other COPD
risk factors), as well as inflammation itself,
can produce oxidative stress that, on the one
hand, primes several inflammatory cells
(macrophages, neutrophils) to release a
combination of proteinases and, on the other
hand, decreases (or inactivates) several
antiproteinases by oxidation. 25
26. • The major proteinases involved in the
pathogenesis of COPD include those produced
by neutrophils (elastase, cathepsin G and
proteinase-3) and macrophages (cathepsins B,
L and S), and various matrix metalloproteinases
(MMP).
• The major antiproteinases involved in the
pathogenesis of COPD include, α1-antitrypsin,
secretory leukoproteinase inhibitor and tissue
inhibitors of MMPs.
• Neutrophil elastase not only contributes to
parenchymal destruction but it is also a very
potent inducer of mucous secretion and mucous
gland hyperplasia. 26
27. Oxidative stress
• Different markers of oxidative
stress are found in increased
amounts in the lungs, exhaled air
breath condensate and urine of
smokers and patients with COPD,
including hydrogen peroxide, nitric
oxide and lipid peroxidation
products (isoprostane F2α-III).
27
28. • Oxidative stress can contribute to
COPD by oxidising a variety of
biological molecules (that can lead to
cell dysfunction or death), damaging
the extracellular matrix, inactivating key
antioxidant defences (or activating
proteinases) or enhancing gene
expression (either by activating
transcription factors (e.g. nuclear factor-
κB) or promoting histone acetylation).
28
29. Pathophysiology
• The different pathogenic mechanisms
discussed above produce the
pathological changes, which, in turn,
give rise to the following physiological
abnormalities in COPD: mucous
hypersecretion and cilliary dysfunction,
airflow limitation and hyperinflation, gas
exchange abnormalities, pulmonary
hypertension, and systemic effects.
29
30. Mucous hypersecretion and cilliary
dysfunction
• These are typically the first physiological
abnormalities in COPD.
• Mucous hypersecretion is due to stimulated
secretion from enlarged mucous glands.
• Cilliary dysfunction due to squamous
metaplasia of epithelial cells. 30
31. Airflow limitation and hyperinflation
• Expiratory (largely irreversible) airflow
limitation is the physiological hallmark of
COPD.
• The major site of the airflow limitation is
in the smaller conducting airways <2
mm in diameter and is mainly due to
airway remodelling (fibrosis and
narrowing).
31
32. • Other factors that also contribute
include loss of elastic recoil (due to
destruction of alveolar walls),
destruction of alveolar support
(alveolar attachments), accumulation
of inflammatory cells, mucous and
plasma exudate in the bronchi, and
smooth muscle contraction and
dynamic hyperinflation during
exercise.
32
33. Gas exchange abnormalities
• These occur in advanced disease and are
characterised by arterial hypoxaemia with or
without hypercapnia.
• An abnormal distribution of ventilation-
perfusion ratios is the main mechanism of
abnormal gas exchange in COPD.
• An abnormal diffusing capacity of carbon
monoxide per litre of alveolar volume
correlates well with the severity of the
emphysema.
33
34. Pulmonary hypertension
• This occurs late in the course of COPD,
normally after the development of severe
gas exchange abnormalities.
• Factors contributing to pulmonary
hypertension in COPD include
vasoconstriction (mostly of hypoxic origin),
endothelial dysfunction, remodelling of
pulmonary arteries and destruction of the
pulmonary capillary bed.
34
35. • This combination of events may eventually
lead to right ventricular hypertrophy and
dysfunction (cor pulmonale).
Systemic effects
• COPD is associated with extrapulmonary
effects, including systemic inflammation and
skeletal muscle wasting.
• These systemic effects contribute to limit the
exercise capacity of these patients and to
worsen prognosis, independent of their
pulmonary function. 35
56. COPD Assessment Test (CAT)
I never cough I cough all the time
I’ve no phlegm in my chest at all My chest is completely full of phlegm
My chest does not feel tight at all My chest feel very tight
When I walk up a hill, I’m not breathless When I walk up a hill, I’m very breathless
I’m not limited doing any activities at
home
I’m very limited doing any activities at
home
I sleep soundly I don’t sleep soundly
I’m confident leaving my home despite
my lung condition
I’m not at all confident leaving my home
despite
I’ve lots of energy I’ve no energy at all
56
67. BODE index
• A multidimensional prognostic index
• Takes into account several indicators of COPD
prognosis (body mass index [BMI], obstructive
ventilatory defect severity, dyspnea severity,
and exercise capacity).
• The components are derived from measures of
the body mass index (weight in kg/heightm2),
FEV1 percent predicted, the modified Medical
Research Council dyspnea and 6 min. walk
Test. 67
68. BODE index
• A BODE score greater than 7 is
associated with a 30 percent 2-year
mortality;
• A score of 5 to 6 is associated with 15
percent 2-year mortality.
• If score is less than 5, the 2-year
mortality is less than 10 percent.
68
73. Therapeutic Options: Smoking
Cessation
• Counseling delivered by physicians and other health
professionals significantly increases quit rates over
self-initiated strategies. Even a brief (3-minute)
period of counseling to urge a smoker to quit results
in smoking quit rates of 5-10%.
• Nicotine replacement therapy (nicotine gum, inhaler,
nasal spray, transdermal patch, sublingual tablet, or
lozenge) as well as pharmacotherapy with
varenicline, bupropion, and nortriptyline reliably
increases long-term smoking abstinence rates and
are significantly more effective than placebo.
73
90. Manage Stable COPD: Pharmacologic
Therapy
(Medications in each box are mentioned in alphabetical order, and therefore not
necessarily in order of preference.)
Patient Recommended
First choice
Alternative choice Other Possible
Treatments
A
SAMA prn
or
SABA prn
LAMA
or
LABA
or
SABA and SAMA
Theophylline
B
LAMA
or
LABA
LAMA and LABA
SABA and/or SAMA
Theophylline
C
ICS + LABA
or
LAMA
LAMA and LABA or
LAMA and PDE4-inh. or
LABA and PDE4-inh.
SABA and/or SAMA
Theophylline
D
ICS + LABA
and/or
LAMA
ICS + LABA and LAMA or
ICS+LABA and PDE4-inh. or
LAMA and LABA or
LAMA and PDE4-inh.
Carbocysteine
SABA and/or SAMA
Theophylline
90
99. Arterial blood gas measurements (in hospital):
PaO2 < 8.0 kPa with or without PaCO2 > 6.7 kPa
when breathing room air indicates respiratory failure.
Chest radiographs: useful to exclude alternative
diagnoses.
ECG: may aid in the diagnosis of coexisting cardiac
problems.
Whole blood count: identify polycythemia, anemia
or bleeding.
Manage Exacerbations: Assessments
99
100. Purulent sputum during an exacerbation:
indication to begin empirical antibiotic
treatment.
Biochemical tests: detect electrolyte
disturbances, diabetes, and poor nutrition.
Spirometric tests: not recommended during
an exacerbation.
Manage Exacerbations: Assessments
100
105. • COPD often coexists with other diseases
(comorbidities) that may have a significant
impact on prognosis.
• In general, presence of comorbidities should
not alter COPD treatment and comorbidities
should be treated as if the patient did not
have COPD.
Comorbidities in COPD
105
107. CAUSES of COMORBIDITIES
• Related to Causes of COPD
– Smoking
– Genetic characteristics of the host
• Related to COPD itself
– Tissue hypoxia
– Inactivity due to dyspnea on exertion
– Pulmonary inflammation/ activation of
inflammatory cells in the lungs
• Not related to COPD 107
111. Right Heart Failure, Cor
pulmonale
• Long-standing
pulmonary
hypertension can
lead to right-sided
heart failure or cor
pulmonale.
• Diagnosis:
– Physical examination
– Chest x-ray
– ECG
• Therapy:
– Oxygen
– Diuretic
– Digitalis, β-bloker
111
112. Pulmonary Hypertension
• Alveolar
hypoxemia and
respiratory acidosis
can cause
pulmonary artery
vasoconstruction
and pulmonary
hypertension.
• Diagnosis:
ABG
Chest x-ray
ECG
Right-sided heart
catheterization
• Therapy:
LTOT
Vasodilator
112
113. Coronary Artery Disease
• Most common cause of death in
cardiovascular disease (50%).
• Smoking and obesity are most common
risk factors.
• Related to systemic inflammation.
113
115. Systemic Hypertension
• Affects
approximately 30
to 37% of adults.
• Prevelance is not
increased in
patient with COPD.
• Blood pressure
monitoring in every
patient.
• Therapy:
– Diuretics
– ACE inh,
– Calcium channel
blockers
– β-blockers (selective)
115
116. Malnutrition and cachexia
• Weight loss and malnutrition occur in up to
50% of persons with COPD.
• More severs in advanced COPD.
• Fat Free Mass (FFM) is important.
116
120. Skeletal Muscle Dysfunction
• The most important
reason is
deconditioning.
• Malnutrition.
• Myopathy from
systemic steroids.
• Skeletal muscle itself
can contribute to
systemic
inflammation. This
has been
demonstrated in
patients with COPD
during exercise.
• Physical exercise and
oxidative stress
increases
plasmaTNF- levels.
• TNF- induce muscle
loss.
Fabbri, ERJ 2008120
121. Osteoporosis
• Postmenopausal
osteoporosis is related
to high serum levels of
TNF- and IL-6.
• Osteopenia found in
COPD is also
associated with an
increase in circulating
TNF- .
• Increased levels of
TNF- (IL-1) stimulate
the differentiation of
macrophages into
osteoclasts.
• Management:
– Early screening
– Exercize
– Calcium 120-
1500mg/day, D vit 400
IU
– Avoidence from
systemic CS
– Biphosphonate
– Calcitonin
– Testesteron
121
122. Diabetes
• Fibrinogen, white blood cell count and
lower albumin predict the development of
type 2 diabetes.
• Patients with type 2 diabetes have
increased levels of TNF- , IL-6 and CRP.
• Diabetes is independently associated with
reduced lung function, which together with
obesity could further worsen the severity
of COPD.
Fabbri, ERJ 2008
122
123. Peptic Ulcus
• Peptic ulceration is more frequent in
patients with COPD.
• Helicobacter sero-positivity is increased in
COPD patients.
Roussos, Respir Med 2005
• Chronic activation of inflammatory
mediators induced by H pylori could
amplify the development of COPD
Sevenoaks, Respir Research 2006
123
124. Sleep Disorders
• Factors associated
with impaired sleep
quality
– Hypoxemia
– Beta-2 agonist
– Cough
– Dyspnea
– Nocturia
– OSAS
• Oxygen
• Treatment against
cough end
dyspnea
• CPAP (OSAS)
124
125. Sexual dysfunction
• Loss of libido and
erectile dysfunction
in more than one
third of patients
with COPD.
• Testesteron levels
below normal.
• Therapy:
– Oxygen.
– Sildenafil might be
considered if there
are no
contraindications.
125